Jim Simons
INKT icon

Jim Simons’s MiNK Therapeutics INKT Stock Holding History

Jim Simons’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,400
Closed -$116K – 3457
2025
Q4 		$116K Sell
10,400
-4,200
-29% -$54.2K ﹤0.01% 2984
2025
Q3 		$204K Buy
+14,600
New +$234K ﹤0.01% 3128
2025
Q1 		– Sell
-10,171
Closed -$70.9K – 3640
2024
Q4 		$70.9K Sell
10,171
-498
-5% -$3.39K ﹤0.01% 3335
2024
Q3 		$80K Sell
10,669
-2,115
-17% -$17.9K ﹤0.01% 3289
2024
Q2 		$121K Buy
12,784
+2,261
+21% +$22K ﹤0.01% 3148
2024
Q1 		$96K Buy
10,523
+1,319
+14% +$12.2K ﹤0.01% 3379
2023
Q4 		$98K Buy
9,204
+3,434
+60% +$35.8K ﹤0.01% 3304
2023
Q3 		$63K Sell
5,770
-8,783
-60% -$143K ﹤0.01% 3352
2023
Q2 		$306K Buy
14,553
+13,523
+1,313% +$271K ﹤0.01% 3115
2023
Q1 		$20K Buy
+1,030
New +$22.3K ﹤0.01% 3821
2022
Q2 		– Sell
-2,576
Closed -$58K – 4398
2022
Q1 		$58K Sell
2,576
-934
-27% -$28.1K ﹤0.01% 3886
2021
Q4 		$157K Buy
+3,510
New +$417K ﹤0.01% 3593

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $666M AUM 28.24% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Jim Simons's INKT Position: Q1 2026 in Review

Jim Simons sold out of MiNK Therapeutics (INKT) in Q1 2026, closing a stake of 10,400 shares — an estimated $116K sold.

Jim Simons first reported a position in INKT in Q4 2021 and held it in 12 quarters. The position peaked at $306K in Q2 2023. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Jim Simons reported no remaining MiNK Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 10,400 MiNK Therapeutics shares in Q1 2026, an estimated $116K.
  • Jim Simons first reported a position in MiNK Therapeutics in Q4 2021 and held it in 12 quarters.
  • Jim Simons's MiNK Therapeutics position peaked at $306K in Q2 2023.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.